Articles with public access mandates - Paolo StratiLearn more
Not available anywhere: 14
Myeloid/lymphoid neoplasms with FGFR1 rearrangement
P Strati, G Tang, DY Duose, S Mallampati, R Luthra, KP Patel, M Hussaini, ...
Leukemia & Lymphoma 59 (7), 1672-1676, 2018
Mandates: US National Institutes of Health
Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection?
C Gudiol, RE Lewis, P Strati, DP Kontoyiannis
The Lancet Haematology 8 (3), e216-e228, 2021
Mandates: Lymphoma Research Foundation, USA
Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms
P Boddu, L Masarova, S Verstovsek, P Strati, H Kantarjian, J Cortes, ...
Annals of Hematology 97, 109-121, 2018
Mandates: US National Institutes of Health
Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function
JR Gunther, C Park, BS Dabaja, SA Milgrom, RJ Cruz Chamorro, ...
Leukemia & Lymphoma 61 (1), 171-175, 2020
Mandates: US National Institutes of Health
Statins enhance the chemosensitivity of R-CHOP in diffuse large B-cell lymphoma
S Gouni, P Strati, G Toruner, A Aradhya, R Landgraf, D Bilbao, F Vega, ...
Leukemia & lymphoma 63 (6), 1302-1313, 2022
Mandates: US National Institutes of Health, Lymphoma Research Foundation, USA
Outcome of relapsed and refractory nodular lymphocyte‐predominant Hodgkin lymphoma: a North American analysis
P Strati, PTM Cheng, RE Steiner, PE Alcedo Andrade, L Feng, D Sano, ...
British Journal of Haematology 192 (3), 560-567, 2021
Mandates: US National Institutes of Health, Lymphoma Research Foundation, USA
Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions
P Strati, P Bose, L Lyle, K Gaw, L Zhou, SA Pierce, J Huynh-Lu, ...
Annals of hematology 96, 733-738, 2017
Mandates: US National Institutes of Health
Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax
ML Marques-Piubelli, EJ Schlette, JD Khoury, F Furqan, F Vega, ...
Leukemia & lymphoma 62 (5), 1129-1135, 2021
Mandates: US National Institutes of Health
Chimeric antigen receptor T-cell therapy for hematologic malignancies: a practical review
P Strati, T Gregory, NS Majhail, N Jain
JCO Oncology Practice 19 (9), 706-713, 2023
Mandates: Lymphoma Research Foundation, USA
Haptoglobin is frequently low in patients with myelofibrosis: Clinical relevance
P Strati, L Masarova, P Bose, N Daver, N Pemmaraju, S Verstovsek
Leukemia Research 57, 85-88, 2017
Mandates: US National Institutes of Health
CAR T-cells and macrophages in large B-cell lymphoma: impact on toxicity and efficacy
A Al Zaki, D McCurry, P Strati
Leukemia & Lymphoma 64 (4), 808-815, 2023
Mandates: US National Institutes of Health, Lymphoma Research Foundation, USA
Interaction between myelomonocytic and lymphoid cells in a patient with acute myelomonocytic leukemia and chronic lymphocytic leukemia
P Strati, JT Manning, CY Ok, G Garcia-Manero, Z Estrov
Leukemia & lymphoma 55 (6), 1425-1427, 2014
Mandates: US National Institutes of Health
Prolonged neurotoxicity in a lymphoma patient after CD19‐directed CAR T‐cell therapy: A case report and brief review of the literature
U Greenbaum, JL Ramdial, A Olson, Y Nieto, P Strati, S Ahmed, ...
Advances in Cell and Gene Therapy 4 (3), e104, 2021
Mandates: Lymphoma Research Foundation, USA
CARDIOVASCULAR EVENTS AMONG ADULT PATIENTS WITH AGGRESSIVE B‐CELL LYMPHOMA TREATED WITH STANDARD OF CARE AXICABTAGENE CILOLEUCEL AND TISAGENLECLEUCEL
R Steiner, J Banchs, E Koutroumpakis, M Becnel, C Gutierrez, P Strati, ...
Hematological Oncology 39, 2021
Mandates: US National Institutes of Health
Available somewhere: 85
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
Q Deng, G Han, N Puebla-Osorio, MCJ Ma, P Strati, B Chasen, E Dai, ...
Nature medicine 26 (12), 1878-1887, 2020
Mandates: US National Institutes of Health
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
CC Pinnix, JR Gunther, BS Dabaja, P Strati, P Fang, MC Hawkins, ...
Blood advances 4 (13), 2871-2883, 2020
Mandates: US National Institutes of Health
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL
P Strati, MJ Keating, SM O'Brien, J Burger, A Ferrajoli, N Jain, ...
Blood, The Journal of the American Society of Hematology 123 (24), 3727-3732, 2014
Mandates: US National Institutes of Health
Venetoclax for AML: changing the treatment paradigm
DA Pollyea, M Amaya, P Strati, MY Konopleva
Blood advances 3 (24), 4326-4335, 2019
Mandates: US National Institutes of Health, Lymphoma Research Foundation, USA
Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
P Strati, H Kantarjian, F Ravandi, A Nazha, G Borthakur, N Daver, T Kadia, ...
American journal of hematology 90 (4), 276-281, 2015
Mandates: US National Institutes of Health
Clinical efficacy of anakinra to mitigate CAR T-cell therapy–associated toxicity in large B-cell lymphoma
P Strati, S Ahmed, P Kebriaei, LJ Nastoupil, CM Claussen, G Watson, ...
Blood Advances 4 (13), 3123-3127, 2020
Mandates: US National Institutes of Health, Lymphoma Research Foundation, USA
Publication and funding information is determined automatically by a computer program